Needham Downgrades IGM Biosciences to Hold
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Matt McGinley has downgraded IGM Biosciences from Buy to Hold.

August 07, 2023 | 4:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
IGM Biosciences has been downgraded from Buy to Hold by Needham analyst Matt McGinley.
The downgrade from Buy to Hold by a Needham analyst indicates a less optimistic outlook for the company's stock, which could potentially lead to a decrease in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100